Healthcare

Verastem Oncology Stock Gains on FDA Fast Track Designation

Compliance Catalyst: Structural Salvage Effort

Co-Diagnostics, Inc. (NASDAQ: CODX) fell roughly 16.88% to about $5.17 on 3 June 2026, ranking among the day's notable decliners. The molecular-diagnostics company saw its shares drop sharply in a session marked by unusually light trading volume, even as the company had recently reported …

Cingulate (Nasdaq:CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention-Deficit/hyperactivity disorder, or ADHD. Its core strategy is built around a proprietary drug-delivery platform designed to release medication in timed doses over the course of a day.

Profit-Taking After a Structural Recovery

The Collapse Explained

Sector Pressure on a Cash-Preserving Platform